Asymptomatic COVID-19 Trial

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: SARS-CoV-2 Infection

In brief

The coronavirus disease-2019 (COVID-19) is spreading throughout the United States. While there are no known therapies to treat those who have become sick, there have been some reports that a medication currently used to treat rheumatoid arthritis, lupus, and malaria (Hydroxychloroquine sulfate, also known as Plaquenil) may help to lessen the chance or severity of illness, especially if combined with a medicine that treats other kinds of infections (Azithromycin, also known as Zithromax or Zmax or Zpak). There are some people who test positive for the virus but who are otherwise not ill. Current standard of care is to advise these people to self-monitor but no treatment is offered. It is not known how many of these individuals will remain symptom free, and how many will become sick or how severe those symptoms will be. This study will randomize those people who do not have symptoms into one of three treatment plans 1) Hydroxycholoquine and Azithromycin, or 2) no active medication (placebo). All participants will be followed for 2 months. The study will determine if there is any benefit to those who are asymptomatic to taking taking Hydroxychloroquine sulfate in combination with Azithromycin, or if there is no benefit from taking these medications.

Key facts

Study ID

NCT04374552

Run by

Rutgers, The State University of New Jersey

People needed

0

Starts

2020-05-05

Expected to finish

2021-04-01

Last updated by the study team

2020-11-02

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented SARS-CoV-2 infection by qPCR assay without symptoms consistent with COVID-19 within 1 week of enrollment
• Age ≥20

You may not qualify if…

• Retinal eye disease
• Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency
• Known chronic kidney disease, stage 4 or 5 or receiving dialysis
• Current use of:
• Class 3 AAD - amiodarone, dronaderone, dofetilide, sotalol)
• Class 1A AAD (procainamide, quinidine, disopyramide)
• Flecainide
• chlorpromazine
• Cilostazol (Pletal)
• Donepezil (Aricept)
• Droperidol
• Fluconazole
• Methadone
• Ondansetron(Zofran)
• Thioridazine
• Macrolides (clarithromycin, erythromycin)
• Fluroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)
• Pregnancy or women who are breast feeding
• Inability to tolerate oral medications
• Allergy or prior adverse reaction to either azithromycin or hydroxychloroquine sulfate
• Allergy to adhesives
• QTc interval > 450 mSEC for men and women
• History of Torsade de Pointes VT or prior cardiac arrest or congenital long QT interval
• Non-English-speaking

Where it is running

• Robert Wood Johnson University Hospital — New Brunswick, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.